Last updated on December 2018

Patients with metastatic prostate cancer will receive either talazoparib or placebo in combination with enzalutamide to determine if the addition of talazoparib to enzalutamide will provide additional benefit when compared to enzalutamide alone.

---

Brief description of study

Randomized, double-blind, placebo-controlled, multinational study comparing talazoparib plus enzalutamide vs. placebo plus enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC).

 

Detailed Study Description

Phase 3